Up 1,460% in a year, the Race (ASX:RAC) share price is sliding today

Up 1,460% in a year, why the Race Oncology (ASX:RAC) share price is sliding today

The Race Oncology (ASX:RAC) share price is slipping in morning trade We take a look at the healthcare company's latest announcement.

Bernd Struben

Author bio Bernd Struben earned his BA in economics from the University of Michigan in 1991, with post-graduate studies in environmental economics at the University of Connecticut. Over the years he’s written about and analysed the tourism industry in the Caribbean; Europe’s commercial real estate markets; and, since moving to Australia in 2010, global and Aussie share markets. Bernd studies geopolitical and macroeconomic trends, alongside sector and company specific data, to gauge what he believes could be tomorrow's best investments. In his free time, you might find Bernd at the beach with his family or working on his next science fiction novel. Areas of expertise Australian and global share markets Macroeconomic and geopolitical trends Real estate Education Economics, University of Michigan Favorite investment quote "The four most dangerous words in investing are: 'This time it's different." — Sir John Templeton

Published March 25, 2021 12:02 pm AEDT

Race Oncology Ltd (ASX: RAC) shares are slipping in late morning trade despite the company providing a positive update. At the time of writing, the Race share price has slumped 1.27% lower to $3.90.

Below we take a look at the ASX healthcare share's collaborative preclinical study announcement.

falling healthcare asx share price Mesoblast capital raising — Image source: Getty Images

What did the company announce?

The Race share price is moving lower after the company reported it has entered into a collaborative preclinical research program with The University of Newcastle.

Well-known cancer researcher, Associate Professor Nikki Verrills, will lead the study. Verrills has previously collaborated with Race in the ASX pharmaceutical company's preclinical breast and ovarian cancer programs.

According to today's release, the collaborative program will use "cellular models to investigate Bisantrene as a novel treatment for clear cell renal cell carcinoma (ccRCC)". ccRCC is a type of kidney cancer, with a 5-year survival rate of only around 12%.

Race's Bisantrene is a targeted inhibitor of the Fat Mass and Obesity associated protein (FTO). According to Race, earlier studies have indicated "FTO enzyme activity is essential for ccRCC survival and the inhibition of FTO can directly kill more than 90% of ccRCCs".

Commenting on the preclinical study, Race Oncology chief scientific officer Daniel Tillett said:

This is a very important project for Race and we are looking forward to collaborating further with Associate Professor Verrills. Recent scientific developments have identified Bisantrene as a potent targeted agent of FTO which offers the possibility of novel treatment options for patients with kidney cancer that can rapidly be translated into the clinic.

We are excited about this research which will further our knowledge of Bisantrene and it adds to the FTO-directed preclinical work we have just initiated in melanoma.

Race said the project will commence immediately and it expects to report results to the market over the next 12 months.

Race Oncology share price snapshot

There's no doubt Race Oncology shareholders who bought shares 12 months ago are pleased. Race shares are up a jaw-dropping 1,460% over the past full year, compared to a gain of 40% on the All Ordinaries Index (ASX: XAO).

So far in 2021, the Race share price is up by 100%.

Automatic Renewal

By taking up this offer, you will also be enrolled in our auto-renewal program, which is our way of making your ongoing subscription easier by ensuring uninterrupted service. Don't worry, though – you're not locked in, and can cancel your auto-renewal at any time before each 'anniversary' date without question or penalty.